<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559455</url>
  </required_header>
  <id_info>
    <org_study_id>OXALI_L_02859</org_study_id>
    <nct_id>NCT00559455</nct_id>
  </id_info>
  <brief_title>Phase II Study of Eloxatin+5-FU/LV in Patients With Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>Phase II Study of Oxaliplatin + 5-FluoroUracil/Leucovorin (Eloxatin+5-FU/LV) in Patients With Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To determine the Tumor Response Rate of patients with hepatocellular carcinoma treated with&#xD;
      the combination chemotherapy of Eloxatin+5-FU/LV&#xD;
&#xD;
      Secondary objective:&#xD;
&#xD;
      To evaluate time to progression, 6month survival, overall survival, safety and tolerability&#xD;
      of patients with hepatocellular carcinoma treated with the combination chemotherapy of&#xD;
      Eloxatin+5-FU/LV&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Response Rate evaluated using RECIST (Response Evaluation Criteria in Solid Tumors) by physical examination, chest X-ray, abdomen-pelvis CT (Computed tomography) scan</measure>
    <time_frame>every 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP), 6 month survival, overall survival, AFP</measure>
    <time_frame>from the signature of Informed Consent up to end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>200mg/m², Day 1 and Day 2; Every 2 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Lists of Inclusion and Exclusion criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed hepatocellular carcinoma&#xD;
&#xD;
          -  Patients must have measurable disease by CT scan&#xD;
&#xD;
          -  Have not received previous palliative systemic chemotherapy for metastatic disease.&#xD;
             (Adjuvant chemotherapy or radiation therapy for non target lesion can be allowed.)&#xD;
&#xD;
          -  Patients progress after previous local treatment and at the time of randomization is&#xD;
             at least 4 weeks after the last interventional therapy (Hepatic Artery Infusion,&#xD;
             Trans-Artery Embolization or Trans-Artery Chemo-Embolization) or at least 4 weeks&#xD;
             after the last radiotherapy/ablation/ Percutaneous Ethanol Injection to the target&#xD;
             lesion.&#xD;
&#xD;
          -  WHO 0-2 grades (Karnofsky Performance Score ≥ 70)&#xD;
&#xD;
          -  Patients must have adequate organ and marrow function:&#xD;
&#xD;
               -  Neutrophilus ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 75 x 10^9/L&#xD;
&#xD;
               -  Asparagine AminoTransferase, Alanine AminoTransferase &lt; 2.5 x Upper Normal&#xD;
                  Limit(UNL)&#xD;
&#xD;
               -  Total Bilirubin ≤ 1.5 x UNL&#xD;
&#xD;
               -  International Normalized Ratio &lt; 1.5&#xD;
&#xD;
               -  Child stage A or B&#xD;
&#xD;
               -  Creatinine ≤ 1.5 X UNL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented allergy to platinum compound or to other study drugs.&#xD;
&#xD;
          -  Active Gastro-Intestinal bleeding and active haematologic malignancy&#xD;
&#xD;
          -  Previous liver transplantation.&#xD;
&#xD;
          -  Patients concomitantly receiving any other anti-cancer therapy.&#xD;
&#xD;
          -  Patients who are receiving any other study treatments.&#xD;
&#xD;
          -  Pregnant or lactating women or women of childbearing potential without proper&#xD;
             contraceptive methods.&#xD;
&#xD;
          -  History of other malignant diseases, except cured basal cell carcinoma of skin and&#xD;
             cured carcinoma in-situ of uterine cervix.&#xD;
&#xD;
          -  Central nervous system metastasis&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
&#xD;
          -  Neuropathy ≥ grade 2&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyang Rim Kim</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>November 15, 2007</study_first_submitted>
  <study_first_submitted_qc>November 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>June 27, 2011</last_update_submitted>
  <last_update_submitted_qc>June 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>Sanofi-aventis Korea</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

